Evidence map›Paper›PMID 35130877›Full record

ArticleBMC medicine2022

Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study.

Giovanni Corrao, Matteo Franchi, Federico Rea, Danilo Cereda, Antonio Barone, Catia Rosanna Borriello, Petra Giulia Della Valle, Michele Ercolanoni, Ida Fortino, Jose Jara and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Giovanni CorraoNational Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy. giovanni.corrao@unimib.it.
Matteo FranchiNational Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
Federico ReaNational Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
Danilo CeredaDirectorate General for Health, Lombardy Region, Milan, Italy.
Antonio BaroneARIA S.p.a., Milan, Italy.
Catia Rosanna BorrielloDirectorate General for Health, Lombardy Region, Milan, Italy.
Petra Giulia Della ValleDirectorate General for Health, Lombardy Region, Milan, Italy.
Michele ErcolanoniARIA S.p.a., Milan, Italy.
Ida FortinoDirectorate General for Health, Lombardy Region, Milan, Italy.
Jose JaraARIA S.p.a., Milan, Italy.
Olivia LeoniDirectorate General for Health, Lombardy Region, Milan, Italy.
Francesco MazziottaDirectorate General for Health, Lombardy Region, Milan, Italy.
Elisabetta PieriniDirectorate General for Health, Lombardy Region, Milan, Italy.
Giuseppe PreziosiARIA S.p.a., Milan, Italy.
Marcello TiraniDirectorate General for Health, Lombardy Region, Milan, Italy.
Massimo GalliInfectious Diseases Unit, Luigi Sacco Hospital, Milan, Italy.
Guido BertolasoChief of the Regional staff for the management of the vaccination campaign, Lombardy Region, Milan, Italy.
Giovanni PavesiDirectorate General for Health, Lombardy Region, Milan, Italy.
Francesco BortolanDirectorate General for Health, Lombardy Region, Milan, Italy.
Regione LombardiaMinistero della Salute · ITUniversity of Milano-Bicocca · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe evolution of SARS-CoV-2 has led to the emergence of several new variants, and few data are available on the impact of vaccination on SARS-CoV-2 variants. We aimed to assess the association between natural (previous infection) and induced (partial or complete vaccination) exposure to SARS-CoV-2 and the onset of new infection supported by the delta variant, and of comparing it with that supported by alpha.

methodsWe performed a test-negative case-control study, by linking population-based registries of confirmed diagnoses of infection with SARS-CoV-2, vaccinations against Covid-19 and healthcare utilization databases of the Italian Lombardy Region. Four hundred ninety-six persons who between 27 December 2020 and 16 July 2021 had an infection by the delta variant were 1:1 matched with citizens affected by alphavariant and 1:10 matched with persons who had a negative molecular test, according to gender, age and date of molecular ascertainment. We used a conditional logistic regression for estimating relative risk reduction of either variants associated with natural and/or induced immunization and corresponding 95% confidence interval (CI).

resultsPrevious infection was associated with 91% (95% CI 85% to 95%) reduced relative risk of reinfection, without evidence of significant differences between delta and alpha cases (p=0.547). Significant lower vaccinal protection against delta than alpha variant infection was observed with reduced relative risk associated with partial vaccination respectively of 29% (7% to 45%), and 62% (48% to 71%) (p=0.001), and with complete vaccination respectively of 75% (66% to 82%) and 90% (85% to 94%) (p=0.003).

conclusionsLower protection towards infections caused by the delta variant with respect to alpha variant was noticed, even after the completion of the vaccination cycle. This finding would support efforts to maximize both vaccine uptake with two doses and fulfilment with individual protection measures, especially as the delta variant is rampant worldwide presently.

Indexed as

COVID-19SARS-CoV-2Case-Control StudiesCOVID-19 VaccinesHumansVaccinationCOVID-19 VaccinesImmunizationPublic healthSARS-CoV-2SARS-CoV-2 variantsVaccination

Identifiers

PMID35130877
PMCPMC8821854
OpenAlexW4210910780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.